FR05C0022I1 - - Google Patents

Info

Publication number
FR05C0022I1
FR05C0022I1 FR05C0022C FR05C0022I1 FR 05C0022 I1 FR05C0022 I1 FR 05C0022I1 FR 05C0022 C FR05C0022 C FR 05C0022C FR 05C0022 I1 FR05C0022 I1 FR 05C0022I1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
Other languages
French (fr)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26306774&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR05C0022(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9506490.3A external-priority patent/GB9506490D0/en
Priority claimed from GBGB9506489.5A external-priority patent/GB9506489D0/en
Application filed filed Critical
Publication of FR05C0022I1 publication Critical patent/FR05C0022I1/fr
Application granted granted Critical
Publication of FR05C0022I2 publication Critical patent/FR05C0022I2/fr
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Medicinal Preparation (AREA)
  • Cephalosporin Compounds (AREA)
FR05C0022C 1995-03-30 2005-05-09 Active FR05C0022I2 (cs)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9506490.3A GB9506490D0 (en) 1995-03-30 1995-03-30 Antiviral combinations
GBGB9506489.5A GB9506489D0 (en) 1995-03-30 1995-03-30 Antiviral combinations
PCT/EP1996/001352 WO1996030025A1 (en) 1995-03-30 1996-03-28 Synergistic combinations of zidovudine, 1592u89 and 3tc or ftc

Publications (2)

Publication Number Publication Date
FR05C0022I1 true FR05C0022I1 (cs) 2005-06-10
FR05C0022I2 FR05C0022I2 (cs) 2005-10-21

Family

ID=26306774

Family Applications (1)

Application Number Title Priority Date Filing Date
FR05C0022C Active FR05C0022I2 (cs) 1995-03-30 2005-05-09

Country Status (35)

Country Link
US (1) US6417191B1 (cs)
EP (1) EP0817637B1 (cs)
JP (1) JP2954357B2 (cs)
KR (1) KR100542536B1 (cs)
CN (1) CN1103593C (cs)
AP (1) AP652A (cs)
AT (1) ATE220551T1 (cs)
AU (1) AU715213B2 (cs)
BR (3) BRPI9612992B1 (cs)
CA (1) CA2216634C (cs)
CZ (1) CZ295940B6 (cs)
DE (3) DE69622386T2 (cs)
DK (1) DK0817637T3 (cs)
EA (1) EA000626B3 (cs)
EE (1) EE04047B1 (cs)
ES (1) ES2179193T3 (cs)
FR (1) FR05C0022I2 (cs)
GE (1) GEP20022647B (cs)
HU (1) HU224010B1 (cs)
IL (1) IL117727A (cs)
LU (1) LU91171I2 (cs)
MX (1) MX9707316A (cs)
MY (1) MY115461A (cs)
NL (1) NL300195I2 (cs)
NO (2) NO313787B1 (cs)
NZ (1) NZ306419A (cs)
OA (1) OA10616A (cs)
PL (1) PL187085B1 (cs)
PT (1) PT817637E (cs)
RO (1) RO117995B1 (cs)
SI (1) SI0817637T1 (cs)
SK (1) SK283825B6 (cs)
TR (1) TR199701074T1 (cs)
UA (1) UA60293C2 (cs)
WO (1) WO1996030025A1 (cs)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20000022226A (ko) * 1996-06-25 2000-04-25 그레이엄 브레레톤;레슬리 에드워즈 Hiv 치료에 사용하기 위한 vx478, 지도부딘, ftc 및(또는) 3tc를 포함하는 배합물
US6113920A (en) * 1996-10-31 2000-09-05 Glaxo Wellcome Inc. Pharmaceutical compositions
TW536403B (en) * 1997-03-24 2003-06-11 Glaxo Group Ltd An ethanol and ethylenediaminetetraacetic acid free pharmaceutical composition comprising lamivudine and exhibiting antimicrobial preservative efficacy
AU769660B2 (en) * 1997-05-17 2004-01-29 Glaxo Group Limited Carbocyclic nucleoside hemisulfate and its use in treating viral infections
GB9709945D0 (en) * 1997-05-17 1997-07-09 Glaxo Group Ltd A novel salt
PE74799A1 (es) * 1997-05-17 1999-08-13 Glaxo Group Ltd Combinaciones antivirales
GB9809213D0 (en) * 1998-04-29 1998-07-01 Glaxo Group Ltd Pharmaceutical compositions
EP1146882A2 (en) * 1998-05-29 2001-10-24 The University Of Florida Combination of zidovudine (azt) with nucleoside analogs for treatment of feline immunodeficiency virus
US6875773B1 (en) 1998-05-29 2005-04-05 Ben M. Dunn Combination therapy for treatment of FIV infection
GB9820417D0 (en) * 1998-09-18 1998-11-11 Glaxo Group Ltd Antiviral combinations
US6432966B2 (en) 1999-10-29 2002-08-13 Smithkline Beecham Corporation Antiviral combinations
US7074417B2 (en) * 2000-10-13 2006-07-11 Advancis Pharmaceutical Corporation Multiple-delayed release anti-viral product, use and formulation thereof
AP2220A (en) * 2001-05-11 2011-03-24 Cipla Medpro Pty Ltd Pharmaceutical composition.
TW200403061A (en) * 2002-06-04 2004-03-01 Glaxo Group Ltd Pharmaceutical compositions
AU2004206821C1 (en) * 2003-01-14 2009-10-01 Gilead Sciences, Inc. Compositions and methods for combination antiviral therapy
RU2344128C2 (ru) 2003-03-24 2009-01-20 Ф.Хоффманн-Ля Рош Аг Бензилпиридазиноны как ингибиторы обратной транскриптазы
JP4931593B2 (ja) 2003-10-24 2012-05-16 イミュネイド ピーティーワイ リミテッド 治療の方法
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
KR20080056220A (ko) 2005-10-19 2008-06-20 에프. 호프만-라 로슈 아게 페닐-아세트아마이드 ｎｎｒｔ 저해제
CN101553483B (zh) 2006-12-13 2013-04-17 弗·哈夫曼-拉罗切有限公司 作为非核苷逆转录酶抑制剂的2-(哌啶-4-基)-4-苯氧基-或苯基氨基-嘧啶衍生物
PL2120878T3 (pl) * 2007-02-09 2015-01-30 Alphapharm Pty Ltd Postać dawkowania zawierająca dwa czynne składniki farmaceutyczne o różnych postaciach fizycznych
CA2763373C (en) 2009-05-27 2018-01-09 Immunaid Pty Ltd Methods and systems for determining preferred times for administering therapy to treat diseases
SI2531027T1 (sl) 2010-01-27 2015-08-31 Viiv Healthcare Company Terapevtska kombinacija, ki obsega dolutegravir, abakavir in lamivudin
CA2918707A1 (en) 2013-08-29 2015-03-05 Teva Pharmaceuticals Industries Ltd. Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir and a monolithic tablet comprising darunavir and ritonavir
CA2942877A1 (en) 2014-04-08 2015-10-15 Nitzan SHAHAR Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir
WO2016023082A1 (en) 2014-08-12 2016-02-18 Monash University Lymph directing prodrugs
JP7118888B2 (ja) 2015-09-08 2022-08-16 モナッシュ ユニバーシティ リンパ指向性プロドラッグ
EP4306524A3 (en) * 2017-08-29 2024-09-11 PureTech LYT, Inc. Lymphatic system-directing lipid prodrugs
US11883497B2 (en) 2017-08-29 2024-01-30 Puretech Lyt, Inc. Lymphatic system-directing lipid prodrugs
US11608345B1 (en) 2017-12-19 2023-03-21 Puretech Lyt, Inc. Lipid prodrugs of rapamycin and its analogs and uses thereof
US11304954B2 (en) 2017-12-19 2022-04-19 Puretech Lyt, Inc. Lipid prodrugs of mycophenolic acid and uses thereof
CA3166908A1 (en) 2020-02-05 2021-08-12 Daniel Kenneth BONNER Lipid prodrugs of neurosteroids

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4724232A (en) * 1985-03-16 1988-02-09 Burroughs Wellcome Co. Treatment of human viral infections
US5047407A (en) 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US5122517A (en) 1988-06-10 1992-06-16 Regents Of The University Of Minnesota Antiviral combination comprising nucleoside analogs
GB8815265D0 (en) * 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
US5204466A (en) 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
GB9009861D0 (en) * 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
GB9104740D0 (en) * 1991-03-06 1991-04-17 Wellcome Found Antiviral nucleoside combination
CZ285232B6 (cs) * 1991-05-16 1999-06-16 Glaxo Group Limited Protivirové směsi
EP0639971B1 (en) * 1992-05-13 1999-09-22 The Wellcome Foundation Limited Therapeutic combinations
US5723490A (en) 1992-09-08 1998-03-03 Vertex Pharmaceuticals Incorporated THF-containing sulfonamide inhibitors of aspartyl protease
GB9417249D0 (en) 1994-08-26 1994-10-19 Wellcome Found A novel salt
US5869461A (en) 1995-03-16 1999-02-09 Yale University Reducing toxicity of L-nucleosides with D-nucleosides
ES2189964T3 (es) 1996-06-25 2003-07-16 Glaxo Group Ltd Combinaciones que comprenden vx478, zidovudina, y 1592u89 para uso en el tratamiento de infecciones por vih.
KR20000022226A (ko) 1996-06-25 2000-04-25 그레이엄 브레레톤;레슬리 에드워즈 Hiv 치료에 사용하기 위한 vx478, 지도부딘, ftc 및(또는) 3tc를 포함하는 배합물
DE10226522A1 (de) 2002-06-14 2003-12-24 Degussa Verwendung von Übergangsmetallkomplexen mit stickstoffhaltigen mehrzähnigen Liganden als Bleichkatalysator und Bleichmittelzusammensetzung

Also Published As

Publication number Publication date
LU91171I2 (fr) 2005-07-04
KR100542536B1 (ko) 2006-03-23
CA2216634A1 (en) 1996-10-03
NO2005014I1 (no) 2005-06-06
KR19980703420A (ko) 1998-11-05
DE69622386T2 (de) 2003-02-13
BR9607851B1 (pt) 2009-01-13
EA199700203A1 (ru) 1998-02-26
JP2954357B2 (ja) 1999-09-27
HUP9801571A2 (hu) 1999-01-28
EP0817637B1 (en) 2002-07-17
SI0817637T1 (en) 2002-10-31
NO974510D0 (no) 1997-09-29
EE04047B1 (et) 2003-06-16
MX9707316A (es) 1997-11-29
UA60293C2 (uk) 2003-10-15
NZ306419A (en) 2000-01-28
PT817637E (pt) 2002-11-29
HU224010B1 (hu) 2005-04-28
BR9607851A (pt) 1998-07-21
JPH10511682A (ja) 1998-11-10
RO117995B1 (ro) 2002-12-30
CZ309097A3 (cs) 1998-05-13
CN1185110A (zh) 1998-06-17
SK129597A3 (en) 1998-07-08
CZ295940B6 (cs) 2005-12-14
NO2005014I2 (no) 2008-02-11
BRPI9607851B8 (pt) 2019-11-05
AU5497296A (en) 1996-10-16
BRPI9612992B1 (pt) 2020-08-04
FR05C0022I2 (cs) 2005-10-21
GEP20022647B (en) 2002-03-25
DE69622386D1 (de) 2002-08-22
CA2216634C (en) 2004-07-20
AP652A (en) 1998-06-19
US6417191B1 (en) 2002-07-09
NL300195I1 (nl) 2005-08-01
TR199701074T1 (xx) 1998-02-21
LU91171I9 (cs) 2018-12-28
PL187085B1 (pl) 2004-05-31
AU715213B2 (en) 2000-01-20
NL300195I2 (nl) 2005-11-01
PL322532A1 (en) 1998-02-02
OA10616A (en) 2001-03-15
AP9701089A0 (en) 1997-10-31
NO313787B1 (no) 2002-12-02
EA000626B1 (ru) 1999-12-29
HUP9801571A3 (en) 2001-04-28
HK1009401A1 (en) 1999-09-10
CN1103593C (zh) 2003-03-26
MY115461A (en) 2003-06-30
NO974510L (no) 1997-09-29
EE9700240A (et) 1998-04-15
IL117727A0 (en) 1996-07-23
SK283825B6 (sk) 2004-02-03
IL117727A (en) 1999-11-30
DE122005000029I1 (de) 2005-10-06
DE122005000029I2 (de) 2006-04-27
DK0817637T3 (da) 2002-11-11
ATE220551T1 (de) 2002-08-15
EA000626B3 (ru) 2016-04-29
EP0817637A1 (en) 1998-01-14
WO1996030025A1 (en) 1996-10-03
ES2179193T3 (es) 2003-01-16

Similar Documents

Publication Publication Date Title
BR122012014331A2 (cs)
BRPI9612258B1 (cs)
BRPI9612138B1 (cs)
FR05C0022I2 (cs)
IN186887B (cs)
IN186501B (cs)
CH0741373H1 (cs)
IN182969B (cs)
FR2729785B1 (cs)
IN186166B (cs)
IN182291B (cs)
IN182456B (cs)
IN185244B (cs)
AU1627395A (cs)
BR7502120U (cs)
BR7501503U (cs)
CN3035300S (cs)
CN3029928S (cs)
CN3037560S (cs)
CN3037433S (cs)
CN3037189S (cs)
CN3030225S (cs)
EP0764970A3 (cs)
CN3036648S (cs)
CN3036647S (cs)